A Phase 2 interventional study of Quadrivalent Influenza Vaccine and Trivalent Influenza Vaccine in Safety Issues, sponsored by PT Bio Farma. Completed at 3 sites in Indonesia. Open to participants aged 6 Months to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-02.
Sponsored by PT Bio Farma · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in Indonesian Population
To describe the protectivity rate of Quadrivalent Influenza HA vaccine 28 days after immunization in Indonesian population.
To describe immunogenicity of quadrivalent Influenza HA vaccine in all subjects
PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for Subjects 9 - 40 Years of Age:
Inclusion Criteria for Subjects 6 Months - 8 Years of Age:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
Biological: Quadrivalent Influenza Vaccine
1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
Biological: Quadrivalent Influenza Vaccine
1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
Biological: Quadrivalent Influenza Vaccine
1 dose of 0.5 ml of trivalent influenza vaccine
Biological: Trivalent Influenza Vaccine
2 dose of 0.25 ml of quadrivalent influenza vaccine
Biological: Quadrivalent Influenza Vaccine
2 dose of 0.5 ml of quadrivalent influenza vaccine
Biological: Quadrivalent Influenza Vaccine
1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
Also known as: QIV
1 dose of Trivalent Influenza Vaccine
Also known as: TIV
Percentage of subjects with an anti-influenza titer >= 1:40 HI units
The anti-influenza antibody serological response
Time frame: 28 days after the last dose immunization
Geometric Mean Titer (GMT)
GMT in all subjects; comparison of GMT between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison of GMT between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old
Time frame: 28 days
Percentage of subjects with increasing antibody titer >= 4 times
Percentage of subjects with increasing antibody titer \>= 4 times: in all subjects; comparison between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old
Time frame: 28 days
Percentage of subjects with transition of seronegative to seropositive
Percentage of subjects with transition of seronegative to seropositive: in all subjects; comparison between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old
Time frame: 28 days
Percentage of subjects with at least one immediate reaction
Immediate reaction (local reaction or systemic event)
Time frame: 30 minutes after each vaccination
Percentage of subjects with at least one of these adverse events
At least one of these adverse events, expected or not
Time frame: within 72 hours, between 72 hours to 28 days after vaccination
Serious adverse event after vaccination
Serious adverse event occurring from inclusion until 28 days after vaccination.
Time frame: 28 days
Comparison adverse events between quadrivalent and trivalent influenza HA vaccine.
Adverse events occuring until 28 days after vaccination
Time frame: 28 days
Comparison of adverse events between each batch number of quadrivalent influenza HA vaccine.
Adverse events occuring until 28 days after vaccination
Time frame: 28 days
Ran from Nov 2017 to primary completion in Mar 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.